RGNX - REGENXBIO Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

REGENXBIO Inc.

9600 Blackwell Road
Suite 210
Rockville, MD 20850
United States
240-552-8181
http://www.regenxbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees192

Key Executives

NameTitlePayExercisedYear Born
Mr. Kenneth T. MillsCEO, Pres & Director808.94k1.28M1975
Mr. Vittal K. VasistaChief Financial Officer502.88kN/A1968
Dr. Olivier DanosChief Scientific Officer466.63kN/A1958
Mr. Curran M. SimpsonSr. VP of Product Devel. & Chief Technology OfficerN/AN/A1962
Mr. Patrick J. Christmas IISr. VP & Gen. CounselN/AN/A1971
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Corporate Governance

REGENXBIO Inc.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.